- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Philips Expands Imaging Capabilities on Handheld Ultrasound Device
In addition to newly added advances with hemodynamic assessment and obstetric measurements, Lumify also offers a B-line quantification tool and AI-enhanced algorithms that may bolster ultrasound lung imaging in severe COVID-19 cases.
Building upon the applications of its handheld, point-of-care ultrasound device Lumify, Philips noted the modality now features advanced hemodynamic assessment as well as obstetric measurement capabilities.
The addition of Pulse Wave Doppler to Lumify enables clinicians to differentiate between arterial and venous blood flow and quantify hemodynamic function. Philips said the hemodynamic measurement capabilities of Lumify can facilitate timely interventions in cardiology and emergency medicine settings. The use of obstetric measurements may also aid in identifying high-risk pregnancies, according to the company.
“With the addition of Pulse Wave Doppler and enhanced obstetric measurements, we have increased the number of markers on which diagnoses can be made to deliver high quality imaging and enhance the evaluation and effectiveness of treatment in real time,” noted Matthijs Groot Wassink, general manager of point of care ultrasound at Philips.
Noting the key role of lung ultrasound in diagnosing pneumonia, a common complication of COVID-19, Philips maintained that Lumify is the only point-of-care ultrasound device that features artificial intelligence (AI)-enhanced B-line quantification. The company said the ability of this technology to assess B-lines in lung fluid may be beneficial for patients with severe cases of COVID-19 infection.
New Study Examines Short-Term Consistency of Large Language Models in Radiology
November 22nd 2024While GPT-4 demonstrated higher overall accuracy than other large language models in answering ACR Diagnostic in Training Exam multiple-choice questions, researchers noted an eight percent decrease in GPT-4’s accuracy rate from the first month to the third month of the study.
FDA Clears AI-Powered Ultrasound Software for Cardiac Amyloidosis Detection
November 20th 2024The AI-enabled EchoGo® Amyloidosis software for echocardiography has reportedly demonstrated an 84.5 percent sensitivity rate for diagnosing cardiac amyloidosis in heart failure patients 65 years of age and older.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
Ultrasound Device Garners FDA De Novo Nod for Kidney Stone Clearance
November 14th 2024Emerging research demonstrated that the Stone Clear device, which facilitates post-lithotripsy clearance of kidney stone fragments, led to a 70 percent lower risk of relapse in comparison to observation in a control group.
